Fredun Pharmaceuticals Reports Strong Q3 FY24-25 Growth Amid Rising Interest Costs

Feb 05 2025 09:37 AM IST
share
Share Via
Fredun Pharmaceuticals has announced its financial results for the quarter ending December 2024, highlighting a year-on-year increase in net sales and profit before tax. The profit after tax reached a five-quarter high, while earnings per share also improved. However, rising interest costs indicate increased borrowings.
Fredun Pharmaceuticals has recently reported its financial results for the quarter ending December 2024, showcasing a range of developments within the company. The financial performance for Q3 FY24-25 indicates a positive trajectory, with net sales reaching Rs 210.05 crore, reflecting a year-on-year growth of 24.30%. This upward trend in sales is complemented by a profit before tax (PBT) of Rs 7.13 crore, which also demonstrates a year-on-year increase of 23.78%.

Notably, the profit after tax (PAT) has reached its highest level in the last five quarters at Rs 5.33 crore, marking a significant year-on-year growth of 26.3%. Additionally, earnings per share (EPS) have peaked at Rs 11.29, indicating enhanced profitability and greater earnings for shareholders.

However, the company has also experienced rising interest costs, with half-yearly interest expenses amounting to Rs 10.31 crore, which reflects a growth of 24.52% compared to the previous half-year period. This increase suggests a rise in borrowings, which may warrant further scrutiny.

Overall, Fredun Pharmaceuticals has undergone an adjustment in its evaluation, maintaining its score over the last three months.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News